Demographics and baseline characteristics of 10 360 participants with usable spirometry data
| Australia | Austria | Canada | China | Germany | Iceland | Kentucky | Norway | Philippines | Poland | South Africa | Sweden | Turkey | UK | |
| N | 558 | 1298 | 845 | 572 | 704 | 760 | 517 | 676 | 916 | 562 | 865 | 553 | 846 | 688 |
| Age (years) | 59.0 (12.4) | 57.7 (11.6) | 56.1 (11.9) | 54.0 (10.9) | 58.2 (11.0) | 56.4 (11.8) | 56.7 (9.9) | 60.1 (12.8) | 52.3 (10.3) | 55.8 (11.6) | 54.2 (10.4) | 58.4 (11.0) | 53.7 (10.6) | 58.2 (11.5) |
| Current smoker, % | 14.3 | 19.2 | 13.5 | 28.2 | 20.6 | 18.3 | 26.3 | 26.0 | 32.4 | 28.8 | 45.9 | 14.7 | 33.7 | 21.1 |
| Cigarette exposure | ||||||||||||||
| Pack-years (full cohort) | 12.4 (25.4) | 13.2 (20.9) | 11.9 (23.4) | 11.1 (17.9) | 15.1 (20.9) | 12.8 (24.9) | 23.4 (29.3) | 12.7 (16.5) | 9.7 (17.1) | 16.1 (25.3) | 11.5 (16.3) | 10.5 (16.2) | 16.0 (27.0) | 16.3 (31.8) |
| Pack-years (ever smokers) | 24.6 (31.3) | 25.3 (23.1) | 22.7 (29.1) | 26.8 (18.8) | 25.1 (21.9) | 21.0 (29.1) | 38.6 (28.9) | 20.1 (16.7) | 18.5 (19.8) | 26.3 (28.0) | 17.0 (17.4) | 18.3 (17.7) | 29.6 (30.8) | 26.3 (36.9) |
| BMI (kg/m2) | 28.0 (5.1) | 26.4 (4.2) | 26.7 (5.2) | 23.2 (3.4) | 27.3 (4.6) | 27.9 (4.9) | 30.7 (6.9) | 26.5 (4.3) | 24.8 (4.7) | 27.6 (4.7) | 27.8 (7.4) | 27.0 (4.4) | 29.5 (5.5) | 27.1 (5.0) |
| Pre-BD FEV1, % pred | 93.3 (18.1) | 92.8 (17.5) | 95.6 (18.4) | 84.8 (14.8) | 95.2 (17.5) | 89.8 (16.4) | 83.4 (18.8) | 92.3 (16.7) | 74.7 (15.4) | 92.2 (18.3) | 76.8 (19.5) | 93.0 (16.1) | 89.0 (18.5) | 87.6 (17.9) |
| Post-BD FEV1, % pred | 95.9 (17.3) | 95.5 (16.7) | 99.2 (17.9) | 86.5 (14.5) | 97.5 (16.9) | 93.0 (16.0) | 86.7 (18.2) | 94.7 (16.5) | 77.0 (15.1) | 94.9 (17.8) | 79.4 (19.0) | 95.8 (16.1) | 92.3 (17.7) | 90.7 (17.3) |
| GOLD stages* | ||||||||||||||
| Stage 1, % | 8.3 | 14.8 | 10.2 | 4.3 | 8.1 | 8.6 | 5.4 | 11.9 | 1.2 | 11.6 | 4.0 | 9.6 | 8.6 | 11.0 |
| Stage 2, % | 9.3 | 8.3 | 6.3 | 5.6 | 5.6 | 6.7 | 10.7 | 7.7 | 7.1 | 8.6 | 13.0 | 4.7 | 9.1 | 9.3 |
| Stage 3, % | 1.3 | 1.1 | 0.7 | 1.5 | 0.7 | 1.6 | 3.7 | 0.9 | 3.7 | 1.8 | 5.8 | 1.5 | 1.1 | 2.1 |
| Stage 4, % | 0.0 | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.5 | 0.7 | 0.0 | 0.6 | 0.0 | 0.4 | 0.2 |
| Any respiratory medication, % | 23.0 | 6.4 | 32.4 | 2.6 | 19.7 | 30.0 | 44.0 | 13.8 | 26.5 | 8.6 | 9.8 | 41.6 | 6.0 | 22.5 |
| Asthma ever, % | 17.2 | 7.1 | 14.3 | 3.2 | 9.7 | 16.7 | 22.1 | 17.3 | 6.6 | 7.3 | 14.7 | 14.5 | 6.4 | 19.5 |
Continuous data presented as mean (SD) unless otherwise stated.
↵* GOLD stage I: FEV1/FVC<70% and FEV1≥80% predicted; GOLD stage II: FEV1/FVC<70% and 50%≤FEV1<80% predicted; GOLD stage III: FEV1/FVC<70% and 30%≤FEV1<50% predicted; GOLD stage IV: FEV1/FVC<70% and FEV1<30% predicted.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FVC, forced vital capacity; Pre-BD FEV1 % pred, pre-bronchodilator FEV1 % predicted; Post-BD FEV1 % pred, post-bronchodilator FEV1 % predicted.